α-Adrenergic agonism enhances the growth hormone (GH) response to GH-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men


Autoria(s): Devesa, J.; Arce, V.; Lois, N.; Lima, L.; Tresguerres, J.A.F.
Data(s)

01/12/1990

Resumo

The purpose of this study was to investigate the precise mechanism by which central a-adrenergic pathways modulate GH secretion in humans. In 10 normal subjects we compared the pattern of clonidine-induced GH release to that elicited by GH-releasing hormone (GHRH) given at a time of presumably similar responsiveness of the somatotrope. We also evaluated the effect of stimulation by GHRH (either endogenous, by administration of clonidine, or exogenous) on the GH response to a further exogenous GHRH stimulation. In 2 experiments the administration of clonidine (0.150 mg, orally) at 0 or 60 min was followed by a GHRH [GRF-(1-29); 1 µg/kg, iv] challenge at 180 min. In other experiments subjects received on separate occasions placebo or clonidine at 0 min, followed by GHRH at 60 min and again at 180 min. In a further experiment the administration of clonidine at 0 min was followed by 2 GHRH challenges (60 and 180 min later). The administration of clonidine 60 or 120 min, but not 180 min, before the GHRH bolus significantly (P <0.01) increased the GH responses to this challenge compared to those elicited by GHRH when given after placebo in a period of a similar somatotrope responsiveness. These, in turn, were significantly (P <0.05) higher than those elicited by clonidine alone. The close relationship between pre-GHRH plasma GH values and GHRH-elicited GH peaks, not observed for clonidine, was lost after pretreatment with this drug. These data indicate that clonidine was able to disrupt the intrinsic hypothalamic-somatotroph rhythm, suggesting that a-adrenergic pathways have a major inhibitory effect on somatostatin release. Our data also indicate that GH responses to a GHRH bolus administered 120 min after a prior GHRH challenge are dependent on two parameters: the intrinsic hypothalamic-somatotroph rhythm at the time of the second GHRH bolus, and the magnitude of GH secretion elicited by the previous somatotroph stimulation. In summary, a-adrenergic agonism appears to act primarily in GH control by inhibiting the hypothalamic release of somatostatin, rather than by stimulating GHRH secretion.

Identificador

http://pure.qub.ac.uk/portal/en/publications/adrenergic-agonism-enhances-the-growth-hormone-gh-response-to-ghreleasing-hormone-through-an-inhibition-of-hypothalamic-somatostatin-release-in-normal-men(762e8441-af27-4b17-bcd6-262d14a41d62).html

http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-0025633550&md5=c7e096e374d7c85e1cc30c4c4f8357d0

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Devesa , J , Arce , V , Lois , N , Lima , L & Tresguerres , J A F 1990 , ' α-Adrenergic agonism enhances the growth hormone (GH) response to GH-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men ' The Journal of clinical endocrinology and metabolism , vol 71 , no. 6 , pp. 1581-1588 .

Tipo

article